CA3024783A1 - Therapeutic uses of l-4-chlorokynurenine - Google Patents

Therapeutic uses of l-4-chlorokynurenine Download PDF

Info

Publication number
CA3024783A1
CA3024783A1 CA3024783A CA3024783A CA3024783A1 CA 3024783 A1 CA3024783 A1 CA 3024783A1 CA 3024783 A CA3024783 A CA 3024783A CA 3024783 A CA3024783 A CA 3024783A CA 3024783 A1 CA3024783 A1 CA 3024783A1
Authority
CA
Canada
Prior art keywords
chlorokynurenine
depression
dose
treatment
tinnitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3024783A
Other languages
English (en)
French (fr)
Inventor
H. Ralph Snodgrass
Allen E. Cato
Jack S. Hicklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vistagen Therapeutics Inc
Original Assignee
Vistagen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics Inc filed Critical Vistagen Therapeutics Inc
Publication of CA3024783A1 publication Critical patent/CA3024783A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3024783A 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine Pending CA3024783A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562179924P 2015-05-22 2015-05-22
US62/179,924 2015-05-22
PCT/US2016/033733 WO2016191351A1 (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine

Publications (1)

Publication Number Publication Date
CA3024783A1 true CA3024783A1 (en) 2016-12-01

Family

ID=57393671

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024783A Pending CA3024783A1 (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine

Country Status (19)

Country Link
US (3) US20180140568A1 (enExample)
EP (2) EP4108239A1 (enExample)
JP (3) JP2018521007A (enExample)
KR (2) KR20240068766A (enExample)
CN (1) CN107949379A (enExample)
AU (3) AU2016268153B2 (enExample)
BR (1) BR112017024908A2 (enExample)
CA (1) CA3024783A1 (enExample)
DK (1) DK3297619T3 (enExample)
EA (1) EA201792571A1 (enExample)
ES (1) ES2925274T3 (enExample)
IL (3) IL296380A (enExample)
MX (1) MX395492B (enExample)
PL (1) PL3297619T3 (enExample)
PT (1) PT3297619T (enExample)
SG (1) SG10202007661XA (enExample)
SI (1) SI3297619T1 (enExample)
WO (1) WO2016191351A1 (enExample)
ZA (1) ZA201707874B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59687B1 (sr) 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MX2021012383A (es) * 2019-04-09 2022-01-04 Vistagen Therapeutics Inc Variantes genéticas asociadas con la respuesta al tratamiento de trastornos neurológicos.
PH12022553441A1 (en) * 2020-06-24 2024-03-04 Biohaven Therapeutics Ltd Compositions and methods for treating obsessive-compulsive disorder
WO2022221423A1 (en) * 2021-04-13 2022-10-20 Vistagen Therapeutics, Inc. Treatment of autoimmune anti-nmda-receptor encephalitis
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
WO2024011105A1 (en) * 2022-07-05 2024-01-11 Mahana Therapeutics, Inc. Methods and systems for treating tinnitus using digital therapeutics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
EP1061924A1 (en) * 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
CA2436311A1 (en) * 2000-12-07 2002-06-13 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
BRPI0709984A2 (pt) * 2006-04-12 2011-08-02 Probiodrug Ag inibidores de enzima
US8058243B2 (en) * 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
JP2011503013A (ja) * 2007-11-06 2011-01-27 エモリー・ユニバーシテイ 安全なｎｍｄａ受容体拮抗薬を同定する方法
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
KR20150096370A (ko) * 2012-08-23 2015-08-24 스튜어트 엘. 웨그 항불안제 조성물, 제형 및 사용방법
RS59687B1 (sr) * 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
CA2941559A1 (en) 2013-03-14 2014-09-25 Vistagen Therapeutics, Inc. Methods for the synthesis of chiral kynurenine compounds
WO2014152835A1 (en) 2013-03-14 2014-09-25 Vistagen Therapeutics, Inc. Synthesis of chiral kynurenine compounds and intermediates
MX2016014581A (es) * 2014-05-06 2018-02-16 Univ Northwestern Composiciones de compuestos que modulan nmdar.

Also Published As

Publication number Publication date
WO2016191351A1 (en) 2016-12-01
ES2925274T3 (es) 2022-10-14
ZA201707874B (en) 2020-01-29
US20180140568A1 (en) 2018-05-24
MX395492B (es) 2025-03-25
MX2017014456A (es) 2018-03-16
IL255770B (en) 2021-09-30
HK1257800A1 (en) 2019-11-01
US20190321317A1 (en) 2019-10-24
BR112017024908A2 (pt) 2018-07-31
AU2016268153B2 (en) 2021-08-12
AU2023282234A1 (en) 2024-01-18
CN107949379A (zh) 2018-04-20
EP4108239A1 (en) 2022-12-28
PL3297619T3 (pl) 2023-02-13
IL285882A (en) 2021-09-30
KR20240068766A (ko) 2024-05-17
JP2022064908A (ja) 2022-04-26
EP3297619B1 (en) 2022-07-06
IL255770A (en) 2018-01-31
EP3297619A4 (en) 2019-01-02
AU2021209279A1 (en) 2021-08-19
KR20180015158A (ko) 2018-02-12
DK3297619T3 (da) 2022-08-15
IL296380A (en) 2022-11-01
EA201792571A1 (ru) 2018-06-29
JP2018521007A (ja) 2018-08-02
AU2016268153A1 (en) 2017-12-14
EP3297619A1 (en) 2018-03-28
PT3297619T (pt) 2022-08-05
AU2021209279B2 (en) 2023-09-14
SI3297619T1 (sl) 2023-02-28
US20240122887A1 (en) 2024-04-18
JP2024050575A (ja) 2024-04-10
SG10202007661XA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
AU2021209279B2 (en) Therapeutic uses of L-4-chlorokynurenine
JP7532021B2 (ja) ムスカリン性受容体活性化によって改善される疾患の治療のための方法および組成物
Detke et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial
Winblad et al. Therapeutic use of nicergoline
Post et al. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response
KR102654569B1 (ko) 외상 후 스트레스 장애의 치료를 위한 제제
JP2019023195A (ja) Ｌ−４−クロロキヌレニンの剤形及び治療的使用
JP2008509147A (ja) ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用
WO2020068913A1 (en) Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine
CN1850271B (zh) 治疗神经衰弱或躯体形式障碍的药物组合物
US20130261165A1 (en) Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
HK40022228B (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
HK40022228A (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
NZ710121B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210521

EEER Examination request

Effective date: 20210521

EEER Examination request

Effective date: 20210521

EEER Examination request

Effective date: 20210521

EEER Examination request

Effective date: 20210521

EEER Examination request

Effective date: 20210521

EEER Examination request

Effective date: 20210521

EEER Examination request

Effective date: 20210521